IP Library Granted Patent US 7,432,250
Granted Patent B2
US 7,432,250 · App. 10/281,312 · Granted Oct 7, 2008

Oligoribonucleotides and ribonucleases for cleaving RNA

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,432,250
App. No.
10/281,312
Granted
Oct 7, 2008
Kind
B2
Abstract

Oligomeric compounds including oligoribonucleotides and oligoribonucleosides are provided that have subsequences of 2′-pentoribofuranosyl nucleosides that activate dsRNase. The oligoribonucleotides and oligoribonucleosides can include substituent groups for increasing binding affinity to complementary nucleic acid strand as well as substituent groups for increasing nuclease resistance. The oligomeric compounds are useful for diagnostics and other research purposes, for modulating the expression of a protein in organisms, and for the diagnosis, detection and treatment of other conditions susceptible to oligonucleotide therapeutics. Also included in the invention are mammalian ribonucleases, i.e., enzymes that degrade RNA, and substrates for such ribonucleases. Such a ribonuclease is referred to herein as a dsRNase, wherein “ds” indicates the RNase's specificity for certain double-stranded RNA substrates. The artificial substrates for the dsRNases described herein are useful in preparing affinity matrices for purifying mammalian ribonuclease as well as non-degradative RNA-binding proteins.

Claims (16)

1. A method of treating a patient having a disease characterized by the undesired production of a protein encoded by a target RNA, comprising administering to said patient a pharmaceutically effective amount of an oligomeric compound, wherein said compound:

(i) is specifically hybridizable with said target RNA;

(ii) is 15 to 25 nucleoside subunits in length;

(iii) comprises a plurality of nucleoside subunits with 2′-hydroxyl pentofuranosyl sugar moieties; and

(iv) comprises at least one modified nucleoside subunit, wherein said modification increases affinity of said compound to said target RNA or increases resistance of said compound to single-stranded nucleases.

2. The method of claim 1 wherein at least one modification is a phosphorothioate internucleoside linkage.

3. The method of claim 1 wherein at least one modification is a 2′-substituted sugar modification.

4. The method of claim 1 wherein at least one modification is a 2′-alkoxy sugar modification.

5. The method of claim 1 wherein at least one modification is a 2′-methoxy sugar modification.

6. The method of claim 1 wherein at least one modification is a 2′-fluoro sugar modification.

7. The method of claim 1 wherein at least one modification is a 2′-methoxyethyl sugar modification.

8. The method of claim 1 wherein said compound is 100% complementary to said target RNA.

9. The method of claim 1 wherein said compound is 17 to 20 nucleoside subunits in length.

10. The method of claim 1 wherein said compound comprises at least four nucleoside subunits with 2′-hydroxyl pentofuranosyl sugar moieties.

11. The method of claim 1 wherein said compound comprises four to twelve nucleoside subunits with 2′-hydroxyl pentofuranosyl sugar moieties.

12. The method of claim 1 wherein said compound comprises five to nine nucleoside subunits with 2′-hydroxyl pentofuranosyl sugar moieties.

Assignments (2)
CHANGE OF NAME Recorded Jul 26, 2017
From: ISIS PHARMACEUTICALS, INC.
To: IONIS PHARMACEUTICALS, INC.
Reel/Frame 043341/0519 →
THIS APPLICATION IS ASSIGNED OF RECORD TO ISIS PHARMACEUTICALS, INC. AS EVIDENCE BY THE ASSIGNMENT FILED AT REEL O13394 AND FRAME NO. 0771 IN DIVISIONAL PARENT APPLICATION SERIAL NO. 09/479,783. Recorded Jul 2, 2003
From: CROOKE, STANLEY T.
To: ISIS PHARMACEUTICALS, INC.
Reel/Frame 013773/0672 →